Al Sandrock, new member of Voyager's board of directors (Biogen via YouTube)
Al Sandrock makes his first post-Biogen move, joining turnaround effort at a troubled gene therapy startup
A few years ago, when Biogen was looking for its next blockbuster, the biotech reportedly considered buying out Voyager Therapeutics.
The deal made intuitive sense. Voyager focused on gene therapies for neurological conditions, combining a technology in which Biogen had shown occasional enthusiasm with a field in which Biogen considered themselves the leading expert. But, as STAT reported last year, Biogen’s conservative board nixed it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
